PP_1170x120_10-25-21

Acura Pharmaceuticals

Acura licenses rights to Nexafed anti-meth decongestant

Acura licenses rights to Nexafed anti-meth decongestant

PALATINE, Ill. — Acura Pharmaceuticals Inc. has entered into a licensing pact that grants exclusive U.S. and Canadian marketing rights to its Nexafed and Nexafed Sinus abuse-resistant decongestant products to MainPointe Pharmaceuticals LLC. Acura said Friday that MainPointe will assume all manufacturing and commercialization activities for the two products. The agreement includes an upfront cash

Fruth recognized for stop-meth efforts

Fruth recognized for stop-meth efforts

POINT PLEASANT, W.Va. — Lynne Fruth, President of Fruth Pharmacy, has been honored for her company’s commitment to help prevent the sale of drugs used in the making of methamphetamine, known as “meth.” At the West Virginia State Capitol Building, Fruth participated in the Our Children, Our Future Policy Summit, where she was asked to

Acura licenses meth-resistant PSE technology to Bayer

Acura licenses meth-resistant PSE technology to Bayer

PALATINE, Ill. — Acura Pharmaceuticals Inc. has licensed its methamphetamine-resistant pseudoephedrine (PSE) technology to Bayer Healthcare LLC for use in future products. Under the license and development agreement announced Tuesday, Acura will provide an exclusive worldwide license to its Impede technology to Bayer for use in an undisclosed meth-resistant, PSE-containing product and to jointly develop

Adheris Health